论文部分内容阅读
应用免疫组化法研究４２例胰腺癌组织中雌激素受体（ＥＲ）、孕酮受体（ＰＲ）和表皮生长因子受体（ＥＧＦＲ）表达及相互关系。ＥＲ、ＰＲ、ＥＧＦＲ阳性率分别为６６．７％、５０％和４５．２％；高分化腺癌和组织学分级Ⅰ级病例ＥＲ、ＰＲ阳性率高于低分化腺癌和组织学分级Ⅲ级病例，ＥＧＦＲ则相反；ＥＧＦＲ阳性病例易发生转移；ＥＲ、ＰＲ表达与ＥＧＦＲ表达存在密切负相关。结果提示：ＥＲ、ＰＲ阳性胰腺癌预后较好，而ＥＧＦＲ阳性胰腺癌预后较差；检测ＥＲ和／或ＰＲ同时检测ＥＧＦＲ可更准确预测胰腺癌激素依赖性和提高内分泌治疗的有效率。
Immunohistochemistry was used to study the expression and relationship of estrogen receptor (ER), progesterone receptor (PR) and epidermal growth factor receptor (EGFR) in 42 cases of pancreatic cancer. The positive rates of ER, PR and EGFR were 66.7%, 50% and 45.2% respectively. The positive rates of ER and PR were higher in well-differentiated adenocarcinoma and histological grade I than in poorly differentiated adenocarcinoma and histological grade III. In case, EGFR is the opposite; EGFR positive cases are prone to metastasis; ER, PR expression is closely related to EGFR expression. The results suggest that ER and PR-positive pancreatic cancers have a good prognosis, while EGFR-positive pancreatic cancers have a poor prognosis. Detecting ER and/or PR and detecting EGFR at the same time can more accurately predict the hormone dependence of pancreatic cancer and increase the efficiency of endocrine therapy.